Weight Loss Surgery for Fatty Liver Disease

Overseen By Coordinator

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington University School of Medicine

Disqualifiers: Organ dysfunction, Tobacco, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

23 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is studying if losing a lot of weight can help reduce liver scarring in people with obesity who have a common liver disease called NAFLD. The goal is to see if weight loss can prevent severe liver problems.

Are You a Good Fit for This Trial?

This trial is for individuals with obesity, specifically those who have a body mass index (BMI) of 35 kg/m2 or higher and are scheduled for weight loss surgery. It's not open to pregnant individuals, people with liver diseases other than NAFLD, those who've had bariatric surgery before, anyone with significant organ dysfunction/disease, tobacco users, or heavy alcohol drinkers.

Exclusion Criteria

Pregnancy

Excessive alcohol use

Tobacco use

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Pre-surgery Assessment

Participants undergo various assessments including genotyping, body composition, and insulin sensitivity before weight loss surgery

Up to 6 months

Weight Loss Surgery

Participants undergo weight loss surgery to achieve significant weight loss

1 visit (in-person)

Post-surgery Follow-up

Participants are monitored for changes in liver fibrogenesis, lipid turnover, and other metabolic functions after weight loss

Up to 6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Weight loss surgery

Trial Overview The study is looking at how effective significant weight loss from bariatric surgery can be on improving liver health in people with non-alcoholic fatty liver disease (NAFLD). The focus is on the rate of hepatic fibrogenesis reduction post-surgery.

How Is the Trial Designed?

Group I: Weight loss Experimental Treatment 1 Intervention

Participants will undergo weight loss surgery

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+